Chartist Requiried, page-26

....... someone in the office might want to tell 4D what Benitec are up to these days.



Benitec Biopharma holds the dominant global patent position for expressed RNA interference (also called DNA-directed RNai (ddRNAi)), placing the company in a commanding position for human therapies associated with specific genes and genetic disorders. The use of shRNA for use in humans falls under Benitec’s patent estate. Benitec’s current clinical pipeline is focused on Hepatitis C, Hepatitis B, lung cancer and wet Age-related Macular Degeneration, as well as the orphan genetic disease, oculopharyngeal muscular dystrophy.